An observational study in Multiple System Atrophy, sponsored by H. Lundbeck A/S. Active, not recruiting at 8 sites in China. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-12-08.
Sponsored by H. Lundbeck A/S · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Multiple System Atrophy with a site in China — 18 open to participants now, 19 under way, 1 of them phase 3. Multiple System Atrophy · China.
Among the 26 studies in Multiple System Atrophy with a site in China, this one is the 7th largest by planned enrollment of the 13 observational ones that give a count, is one of 2 that started in 2022, is one of 13 observational ones, reaches primary completion later than 0 of the 18 other live ones, and was the 5th registered.
207 studies on the registry are indexed under Multiple System Atrophy; 73 are open to participants now.
Browse Multiple System Atrophy studies →18 of the 26 studies in Multiple System Atrophy with a site in China are open now. Recruiting first, the newest first:
Second Affiliated Hospital, Zhejiang University, School of Medicine · Sites in China
Ages 30–80
yilong Wang · Sites in China
Ages 30–75
Synusight Biotech (Shanghai) Co., Ltd. · Sites in China
Ages 18+ · Healthy volunteers
yilong Wang · Sites in China
Ages 30–75
iRegene Therapeutics Co., Ltd. · Sites in China
Ages 30–70
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 57 Multiple System Atrophy studies recruiting now, 24 (42%) set no upper age limit and 11 (19%) stop at 75 or younger; 7 take children under 18; 18 take healthy volunteers.
This study: 40 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 1 · Phase 3 2
First in 2019; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 90 is below the median of 196 across 67 observational studies indexed under Multiple System Atrophy.
Median enrollment 30 across the 13 interventional studies, 90 across the 13 observational. Of the 4 that completed or were terminated, 1 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 26 have an industry lead sponsor. The 10 most frequent:
H. Lundbeck A/S is the lead sponsor of 224 studies on the registry; 9 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 10 (30%) have results posted.
H. Lundbeck A/S has 7 studies filed under Multiple System Atrophy — fewer than ten, so there is no comparison to draw.
11 of the studies in Multiple System Atrophy with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07518810Phase 3Second Affiliated Hospital, Zhejiang University, School of MedicineEfficacy and Safety of Butylphthalide in the Treatment of Multiple System Atrophy | 2027-04-10 |
| NCT07604116Synusight Biotech (Shanghai) Co., Ltd.A Study to Evaluate Satety, Tolerability, Biodistribution, Radiation Dosimetry, and Pharmacokinetics of SST001 in Healthy Volunteers, Patients With PD and Patients With MSA | 2026-12 |
| NCT07774585Ruijin HospitalA Prospective Exploratory Study of the Safety and Preliminary Efficacy of the α-Syn H21 Monoclonal Antibody in Patients With Multiple System Atrophy | 2026-12-31 |
| NCT07353463Ruijin HospitalShanghai Clinical Cohort - Parkinson's Disease (Reserve) | 2026-12-31 |
| NCT07392411Beijing Tiantan HospitalStudy on Artificial Intelligence-Based Facial and Speech-Related Patterns in Parkinson's Disease and Their Digital Biomarkers | 2026-12-31 |
Add all 11 to your calendar (.ics) → With an account.
Among the 26 studies in Multiple System Atrophy with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Talisman is global clinical study (20058N) in Multiple System Atrophy (MSA) patients. It will be conducted in two regions (China and the European Union [EU]). There will be common study objectives between China and EU regions (including prospective assessments for MSA disease progression during routine clinical visits for MSA), and this will allow for data (on common objectives) to be presented overall and stratified by region. There will also be study objectives specific to each region: 1) the clinical assessment for MSA (Unified MSA Rating Scale [UMSARS]) has not been validated using standardised methods in China, and so the psychometric properties of the Chinese version of the UMSARS will be examined in Chinese patients in this study; 2) there will be retrospective assessments and prospective protocol-mandated assessments (of Magnetic Resonance Imaging [MRI] and bloods biomarkers) and study visits for EU patients.
Because some study objectives are the same for China and the EU (i.e., prospective assessments during routine clinical visits for MSA), and other objectives are specific to each region, there will be one regional protocol for China and one regional protocol for the EU; each describing the study assessments relevant to each region.
Multiple system atrophy (MSA) is a sporadic, rapidly progressing neurodegenerative disorder. Most MSA patients are diagnosed between 50 to 60 years of age and the mean survival time is 6 to 10 years from symptom onset, with few surviving more than 15 years from symptom onset. The rapid progression and complexity of the disease, as well as its unresponsiveness to drugs, such as Levodopa for parkinsonian symptoms, makes MSA a challenging disease to treat. Based on the predominant motor features at the time of clinical evaluation, MSA is classified as either MSA with predominant parkinsonism (MSA-P) or MSA with predominant cerebellar ataxia (MSA-C).
MSA is an orphan and rare disease. The prevalence estimate of MSA is 3 to 5 per 100,000 in the general population. The prevalence estimate ranges from 2 to 5 per 100,000 in the United States and European Union (EU) and from 7 to 20 per 100,000 in Japan. MSA-P comprises approximately 70% of cases in the US and EU, whilst MSA-C comprises approximately 70% of cases in Japan.
Blood and MRI biomarkers have been evaluated in MSA patients. NfL (Neurofilament light protein) levels are increased in the cerebrospinal fluid (CSF) and plasma of patients with MSA and correlate with MSA disease severity, as measured by the unified MSA rating scale (UMSARS). An accurate estimate of NfL levels over time could help monitor MSA prognosis and help define the timepoints that could be targeted for effective treatment.
Furthermore, MSA patients with abnormal brain MRI findings have faster clinical progression of MSA, as evaluated with the UMSARS total score and UMSARS Part II (clinical examination). A recent review on the role of MRI in MSA noted that whilst MRI is a promising tool for diagnosing and monitoring disease progression; well-designed, large, prospective studies are needed before MRI biomarkers could be incorporated into a neuroimaging-supported diagnosis of MSA. The knowledge gained from this study should help improve understanding of biomarkers and other disease progression outcomes in MSA. This could allow MSA disease progression to be monitored and therefore treated more effectively. Insights into the natural course of disease in MSA patients in the EU will be combined and compared with data on the natural course of disease in MSA patients in China, as part of a larger global cohort. Specifically, the natural course of MSA will be explored in patients in China (using [Chinese versions of] the same prospective observational assessments as the current prospective protocol in the EU). This will allow for data collected prospectively during routine visits for MSA in China to be combined and compared with data collected prospectively during routine visits for MSA in the EU.
The extension part of Talisman:
The extension of Talisman will describe early MSA disease progression and mortality assessed remotely via telephone call with either the participant or care-partner in 6-month intervals up until 60 months after enrolling in extension study. The long-term extension will generate knowledge on long-term disease progression and survival in MSA.
Approximately 140 patients with relatively early MSA from China and EU are expected to be enroled in this study during a 9-month enrolment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This protocol does not mandate the use of any treatments. No study medication will be administered as part of study participation. Any treatment that study patients receive will be prescribed according to the recommendations given in the local SmPCs.
Diagnostic Test: plasma NfL and brain MRI (vMRI, DTI, and ASL [if feasible]) only for the EU cohort
Biomarker assessments are mandated in this protocol (i.e., they are not expected to be done as part of routine clinical practice). These assessments will be conducted within the same time window as the observational assessments (at approx. 6-month intervals) and are mandated by protocol if not conducted as per clinical practice.
To describe early MSA disease progression changes in 6-month intervals over 12-months (i.e., baseline, 6-months, 12-months)
Disease progression will be assessed using the Unified MSA Rating Scale (UMSARS) Part I and II (scores ranging from 0-104); higher scores indicate greater impairment
Time frame: baseline, 6 months, 12 months
Changes from baseline to approx. 6-months after baseline and approx.12- months after baseline in plasma NfL concentrations.
Time frame: baseline, 6 months, 12 months
Percentage change in brain volume in brain regions-of-interest (ROIs), as measured by volumetric MRI (vMRI).
Time frame: baseline, 6 months, 12 months
Percentage change in tissue integrity in ROIs, as measured by diffusion-tensor imaging (DTI) MRI.
Time frame: baseline, 6 months, 12 months
To evaluate changes from baseline on the impact of disease progression on the quality of life (QoL) of the patient at 6 and 12 months
Patient QoL will be measured by the European Quality of Life Five Dimensions questionnaire 5 level version (EQ-5D-5L)
Time frame: baseline, 6 months, 12 months
To evaluate changes from baseline on the impact of disease progression on the quality of life (QoL) of the caregiver at 6 and 12 months
Caregiver QoL will be measured by the Parkinsonism Carers Quality of Life scale (PQoLCarers) (score range 0-104); higher score indicate worse QoL
Time frame: baseline, 6 months, 12 months
To assess changes on the burden of orthostatic hypotension at 6 and 12 months from baseline
Othostatic hypertension will be measured by the Orthostatic Hypotension Questionnaire (OHQ) (scores ranging from 0-100); higher scores indicate greater impairment
Time frame: baseline, 6 months, 12 months
To describe occurrence of MSA subtypes and disease progression in each MSA subtype
MSA subtype (i.e., MSA-P vs MSA-C) at each study site; disease progression will be measured by UMSARS
Time frame: baseline, 6 months, 12 months
To assess the prevalence of "responders to Levodopa" (as per clinical judgement) at baseline and who continue to respond at 6 and 12 months from baseline
Time frame: baseline, 6 months, 12 months
To describe Levodopa dose modifications from baseline to 6 and 12 months
Time frame: baseline, 6 months, 12 months
To describe patient characteristics of responders to Levodopa versus non-responders to Levodopa, including: age (in years) at MSA onset, sex (male, female), MSA diagnosis (probable versus possible), MSA subtype (MSA-P versus MSA-C).
Time frame: baseline, 6 months, 12 months
To characterise MSA symptoms and their progression over time
MSA symptoms as per the following single items in UMSARS Part I (historical review): * Urinary incontinence (item 10) * Falling (item 8) * Speech (item 1) * Swallowing (item 2) * Walking (item 7)
Time frame: baseline, 6 months, 12 months
To assess the psychometric properties of the Chinese version of UMSARS.
To test the reliability and validity of the Chinese version of the UMSARS
Time frame: baseline, 6 months, 12 months
To confirm the psychometric properties of the UMSARS
To confirm the reliability and validity of the UMSARS Evaluation of UMSARS equivalence using Retrospective and Prospective Cohort data
Time frame: baseline, 6 months, 12 months
To describe early MSA disease progression and mortality assessed remotely in 6-month intervals up until 60 months after enrolling in extension study.
Disease progression in the extension will be assessed using: * UMSARS Part I * Mortality (date and cause of death)
Time frame: 6-month intervals up until 60 months
Ran from Jun 2022 to primary completion in Mar 2024, 20 months.
Of 39 observational studies under Multiple System Atrophy, half reached primary completion within 94 months of starting (the median), counting those still running; a quarter within 37. This study's 20 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.